Nachrichten zur Eagle Pharmaceuticals Aktie

Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX)…

SEEDS - ACCESS CHANGES EVERYTHING HONORS EAGLE PHARMACEUTICALS AND ALUMNA NASHEENA PORTER POZNANSKY

NEWARK, N.J., Feb. 15, 2023 /PRNewswire/ -- SEEDS - Access Changes Everything, an educational nonprofit that has been providing education…

Form 8-K EAGLE PHARMACEUTICALS, For: Jan 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Eagle Pharma sets 2023 guidance in line with consensus

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Eagle Pharmaceuticals Provides Business Update and Guidance for 2023

WOODCLIFF LAKE, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”)…

Form 8-K/A EAGLE PHARMACEUTICALS, For: Jan 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K EAGLE PHARMACEUTICALS, For: Jan 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

WOODCLIFF LAKE, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”)…

Form 8-K EAGLE PHARMACEUTICALS, For: Dec 19

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Eagle Pharmaceuticals Gets FDA Approval for New Pemfexy Indication

Eagle Pharmaceuticals Gets FDA Approval for New Pemfexy Indication...…

Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy

-- Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR…

Form 8-K EAGLE PHARMACEUTICALS, For: Dec 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Are Investors Undervaluing Eagle Pharmaceuticals (EGRX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

Eagle Pharmaceuticals Reaches Settlement Agreement with Accord Healthcare, Inc. Related to BENDEKA® (bendamustine hydrochloride)

WOODCLIFF LAKE, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”)…

Form 8-K EAGLE PHARMACEUTICALS, For: Dec 06

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K EAGLE PHARMACEUTICALS, For: Nov 14

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia

-- Expect to begin a Phase 2 study in approximately 276 patients with severe community-acquired pneumonia at approximately 120 sites…

Form 10-Q EAGLE PHARMACEUTICALS, For: Sep 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K/A EAGLE PHARMACEUTICALS, For: Nov 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Correcting & Replacing: Eagle Pharmaceuticals Reports Third Quarter 2022 Results

WOODCLIFF LAKE, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its…

Eagle Pharmaceuticals Shares Rise 22% After 3Q Adj EPS Beat Expectations

Eagle Pharmaceuticals Shares Rise 22% After 3Q Adj EPS Beat Expectations...…

Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do…

Eagle Pharmaceuticals Reports Third Quarter 2022 Results

WOODCLIFF LAKE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”)…

Form 8-K EAGLE PHARMACEUTICALS, For: Nov 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Eagle Pharmaceuticals Q3 2022 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Eagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022

WOODCLIFF LAKE, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX)…

SAVE THE DATE: Eagle Pharmaceuticals to Host Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

WOODCLIFF LAKE, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”)…

Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial Pne

-- Company plans to commence an adequately powered Phase 2 study with approximately 276 patients with severe community-acquired pneumonia at…

Eagle Pharmaceuticals Gets FDA Designation for Infant Apnea Treatment

Eagle Pharmaceuticals Gets FDA Designation for Infant Apnea Treatment...…

Form 8-K EAGLE PHARMACEUTICALS, For: Oct 03

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Eagle Pharmaceuticals and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001 for the Treatment of Apnea of Prematurity, a New Chemical Entity Being Developed as an Agnostic Respiratory Stimulant

-- ENA-001, with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease…

dpa-AFX ProFeed